Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach
Laupacis A, Paterson JM, Mamdani M, Rostom A, Anderson GM. CMAJ. 2003; 169(11):1167-70.
Publications
What Effects do Provincial Drug Plan Coverage Policies for New Drugs have on Patterns of Use and Cost?
Use of antidepressants among Canadian workers receiving depression-related short-term disability benefits
Dewa CS, Hoch JS, Goering P, Lin E, Paterson M. Psychiatr Serv. 2003; 54(5):724-9.
Primary prevention drug therapy: can it meet patients’ requirements for reduced risk?
Llewellyn-Thomas HA, Paterson JM, Carter JA, Basinski A, Myers MG, Hardacre GD, Dunn EV, D'Agostino RB, Wolf PA, Naylor CD. Med Decis Making. 2002; 22(4):326-39.
Depression-related short-term disability in an employed population
Dewa CS, Goering P, Lin E, Paterson M. J Occup Environ Med. 2002; 44(7):628-33.
Hospital Funding for New Drug Technologies
Using disease risk estimates to guide risk factor interventions: field test of a patient workbook for self-assessing coronary risk
Paterson JM, Llewellyn-Thomas HA, Naylor CD. Health Expect. 2002; 5(1):3-15.
“Trial” prescriptions to reduce drug wastage: results from Canadian programs and a community demonstration project
Paterson JM, Anderson GM. Am J Manag Care. 2002; 8(2):151-8.
Focus Groups in Health Services Research at ICES
In the queue for coronary artery bypass grafting: patients’ perceptions of risk and ‘maximal acceptable waiting time’
Llewellyn-Thomas H, Thiel E, Paterson J, Naylor D. J Health Serv Res Policy. 1999; 4(2):65-72.